Journal of Hematological Malignancies（ISSN 1925-4024，EISSN 1925-4032）is an open access international scientific journal providing a forum for peer-reviewed articles, reviews or commentary related to all aspects of the prevention, diagnosis and management of malignancies of the blood system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and randomized controlled trials and evidence-based meta-analysis or pooled analysis related to specific trials.
JHM is included in:
- Gale's Academic Databases
- Google Scholar
- PKP Open Archives Harvester
- The Standard Periodical Directory
Original Research, Case Report, Conference Report, Reviews.
2013 Q1: Articles Received: 8; Accepted: 4; Rejected: 7; Published: 5; Retracted: 2
2013 Q2: Articles Received: 10; Accepted: 3; Rejected: 9; Published: 2; Retracted: 1
What is e-Version FirstTM
e-Version First is a feature offered through our journal platform. It allows PDF version of manuscripts that have been peer reviewed and accepted, to be hosted online prior to their inclusion in a final printed journal. Readers can freely access or cite the article. We aim to publish accepted manuscripts in e-Version First in two week's time after the final draft completed.
Paper Selection and Publication Process
a). Upon receipt of paper submission, the Editor sends an E-mail of confirmation to the corresponding author within 1-3 working days. If you fail to receive this confirmation, your submission/e-mail may be missed. Please contact the Editor in time for that.
b). Peer review. We use double-blind system for peer-review; both reviewers and authors' identities remain anonymous. The paper will be peer-reviewed by three experts; two reviewers from outside and one editor from the journal typically involve in reviewing a submission. The review process may take 2-3 weeks.
c). Notification of the result of review by E-mail.
d). The authors revise paper and pay publication fee (200.00 USD).
e). After publication, the corresponding author will receive two copies of printed journals, free of charge.
f). E-journal in PDF is available on the journal’s webpage, free of charge for download.
The publisher and journal have a policy of “Zero Tolerance on the Plagiarism”. We check the plagiarism issue through two methods: reviewer check and plagiarism prevention tool (ithenticate.com).
All submissions will be checked by iThenticate before being sent to reviewers.
Special Issue Guideline
|Special Issues are an important component of The Journal of Hematological Malignancies (JHM)edited by a Guest Editor.|
New Issue Published
|Journal of Hematological Malignancies has just published its latest issue.|
Free of Charge for the first\ second issue
|The very first/second issue of the Journal of Biomedical Graphics and Computing is in the process of calling for papers.|
Journal of Hematological Malignancies(JHM)formed Editorial Review Board
|JHM'S Editorial Review Board has been established, consisting of more than 80 surgeons, radiologists, researchers and experts in blood-related conditions, as well as the treatment of hematological malignancies area.
Vol 3, No 2 (2013)
Table of Contents
|Curcumin enhances the cytotoxic and chemo-sensitising effects of lenalidomide in human multiple myeloma cells|
|Rose Wong, Terry Golombick, Terrence H. Diamond, Arumugam Manoharan, Rajeev Ramakrishna||p1|
|Retrospective study of quantitative free light chain levels in random urine of patients with multiple myeloma|
|Jozef Malysz, Junjia Zhu, Michael H. Creer, Nathan G. Dolloff, Michael G. Bayerl, Giampaolo Talamo||p8|
|Mutation analysis and prenatal diagnosis of a Chinese family with Fanconianemia|
|Zhuwen Gong, Qigang Zhang, Xuefan Gu||p24|
|Identification of patients with defects in the globin genes by analysing blood parameters and genetic study: Report of five cases|
|Domenico Dell'Edera, Michele Benedetto, Manuela Leo, Carmela Santacesaria, Arianna Allegretti, Maria Giovanna Lupo, Eleonora Mazzone, Annunziata Anna Epifania||p29|
|Acquired Pure Red Cell Aplasia in patients with plasma cell neoplasm and long term remission with bortezomib therapy|
|Kiran S Sarathy, Raj Ramakrishna, Waqas W Baig, Arumugum Manoharan||p37|
|An update on the management of systemic lupus erythematosus|
|Ragan Sweet, Soheyla Mahdavian, Angela Singh, Patty Ghazvini, Ta’Shae McKinnon, Deidra Jones||p16|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Sciedu Press
To make sure that you can receive messages from us, please add the 'Sciedu.ca' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders